CN113396157A - 具有降低的胰岛素受体结合亲和力的胰岛素类似物 - Google Patents

具有降低的胰岛素受体结合亲和力的胰岛素类似物 Download PDF

Info

Publication number
CN113396157A
CN113396157A CN201980091275.1A CN201980091275A CN113396157A CN 113396157 A CN113396157 A CN 113396157A CN 201980091275 A CN201980091275 A CN 201980091275A CN 113396157 A CN113396157 A CN 113396157A
Authority
CN
China
Prior art keywords
insulin
glu
val
chain
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091275.1A
Other languages
English (en)
Chinese (zh)
Inventor
T·勃姆
S·居斯雷根
M·H·科恩
M·威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68806785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113396157(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CN113396157A publication Critical patent/CN113396157A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980091275.1A 2018-12-11 2019-12-10 具有降低的胰岛素受体结合亲和力的胰岛素类似物 Pending CN113396157A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18306657.0 2018-12-11
EP18306659.6 2018-12-11
EP18306658 2018-12-11
EP18306659 2018-12-11
EP18306658.8 2018-12-11
EP18306657 2018-12-11
PCT/EP2019/084427 WO2020120477A1 (en) 2018-12-11 2019-12-10 Insulin analogs having reduced insulin receptor binding affinity

Publications (1)

Publication Number Publication Date
CN113396157A true CN113396157A (zh) 2021-09-14

Family

ID=68806785

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980091275.1A Pending CN113396157A (zh) 2018-12-11 2019-12-10 具有降低的胰岛素受体结合亲和力的胰岛素类似物
CN201980091302.5A Pending CN113423691A (zh) 2018-12-11 2019-12-10 肽结合剂
CN201980091301.0A Pending CN113395982A (zh) 2018-12-11 2019-12-10 胰岛素缀合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980091302.5A Pending CN113423691A (zh) 2018-12-11 2019-12-10 肽结合剂
CN201980091301.0A Pending CN113395982A (zh) 2018-12-11 2019-12-10 胰岛素缀合物

Country Status (15)

Country Link
US (3) US11098102B2 (enExample)
EP (3) EP3894435A1 (enExample)
JP (3) JP2022513776A (enExample)
KR (3) KR20210102347A (enExample)
CN (3) CN113396157A (enExample)
AU (3) AU2019398579A1 (enExample)
BR (3) BR112021011050A2 (enExample)
CA (3) CA3122632A1 (enExample)
CO (1) CO2021007453A2 (enExample)
IL (3) IL283803A (enExample)
MX (3) MX2021006970A (enExample)
PH (1) PH12021551339A1 (enExample)
SG (3) SG11202106167XA (enExample)
TW (3) TW202039438A (enExample)
WO (3) WO2020120479A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210102347A (ko) 2018-12-11 2021-08-19 사노피 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
CN112876388B (zh) * 2021-01-14 2023-03-31 山东大学 一种gpr120激动剂及其制备方法与应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114230451A (zh) * 2021-12-29 2022-03-25 上海药坦药物研究开发有限公司 卤代酸类化合物的制备方法
EP4469088A1 (en) * 2022-01-26 2024-12-04 Sanofi Insulin conjugates
JP2025522529A (ja) 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのＦｃ結合体
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用
CN118063589A (zh) * 2024-02-04 2024-05-24 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
CZ289343B6 (cs) 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP1974729A1 (en) * 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102065903B (zh) 2008-04-01 2015-02-18 诺沃-诺迪斯克有限公司 胰岛素清蛋白缀合物
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP2012511506A (ja) 2008-12-09 2012-05-24 ノヴォ・ノルディスク・アー／エス 新規インスリンアナログ
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
MX2012012943A (es) 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
WO2012049307A2 (en) 2010-10-15 2012-04-19 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
KR20150021011A (ko) * 2011-10-27 2015-02-27 케이스 웨스턴 리저브 유니버시티 초고도 농축된, 속효성 인슐린 유사체 제형
CN104011070A (zh) 2011-12-15 2014-08-27 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
KR20140104994A (ko) 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
US20140357838A1 (en) 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
AU2013337250B2 (en) 2012-11-05 2017-06-22 Case Western Reserve University Long-acting single-chain insulin analogues
DK2963056T3 (da) 2013-02-26 2020-02-17 Hanmi Pharm Ind Co Ltd Insulinanalog og anvendelse deraf
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
CN105188736A (zh) 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
JP6347451B2 (ja) * 2013-08-02 2018-06-27 国立大学法人富山大学 （ベンゼンスルホニルアミノ）ベンズアミド誘導体およびそれらを有効成分とするｓｈｉｐ２阻害剤
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
WO2016001185A1 (en) 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
WO2016119854A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US11097046B2 (en) 2015-08-25 2021-08-24 Novo Nordisk A/S Medical injection device with a cleaning chamber
CN108368163A (zh) 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
PL239062B1 (pl) 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
WO2018024186A1 (zh) 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
CA3294636A1 (en) 2016-11-21 2026-02-10 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
WO2018107117A1 (en) * 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
JP2021014409A (ja) * 2017-11-21 2021-02-12 京都薬品工業株式会社 タンパク質結合性薬物
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
KR20210102347A (ko) 2018-12-11 2021-08-19 사노피 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
KR20220112817A (ko) 2019-12-10 2022-08-11 사노피 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법

Also Published As

Publication number Publication date
US20200181223A1 (en) 2020-06-11
US11098102B2 (en) 2021-08-24
MX2021006969A (es) 2021-07-15
EP3893934A1 (en) 2021-10-20
MX2021006972A (es) 2021-08-16
AU2019398579A1 (en) 2021-07-29
MX2021006970A (es) 2021-07-15
CO2021007453A2 (es) 2021-06-21
US12195510B2 (en) 2025-01-14
BR112021011156A2 (pt) 2021-10-26
US20220048968A1 (en) 2022-02-17
WO2020120477A1 (en) 2020-06-18
CN113423691A (zh) 2021-09-21
EP3893934B1 (en) 2025-09-10
CA3122636A1 (en) 2020-06-18
TW202039438A (zh) 2020-11-01
US20250206798A1 (en) 2025-06-26
IL283801A (en) 2021-07-29
JP2022511567A (ja) 2022-01-31
JP2022513775A (ja) 2022-02-09
JP2022513776A (ja) 2022-02-09
PH12021551339A1 (en) 2021-11-29
BR112021011050A2 (pt) 2021-08-31
WO2020120463A1 (en) 2020-06-18
CA3122637A1 (en) 2020-06-18
WO2020120479A1 (en) 2020-06-18
TW202039539A (zh) 2020-11-01
KR20210102346A (ko) 2021-08-19
EP3894435A1 (en) 2021-10-20
EP3894391A1 (en) 2021-10-20
IL283803A (en) 2021-07-29
CA3122632A1 (en) 2020-06-18
CN113395982A (zh) 2021-09-14
KR20210102345A (ko) 2021-08-19
IL283800A (en) 2021-07-29
SG11202106167XA (en) 2021-07-29
SG11202106166TA (en) 2021-07-29
BR112021011099A2 (pt) 2021-10-26
TW202039437A (zh) 2020-11-01
SG11202106168VA (en) 2021-07-29
KR20210102347A (ko) 2021-08-19
AU2019398402A1 (en) 2021-07-29
AU2019398658A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CN113396157A (zh) 具有降低的胰岛素受体结合亲和力的胰岛素类似物
JP5710253B2 (ja) 速効型インスリンアナログ
RU2678134C2 (ru) Конъюгаты инсулин-инкретин
JP6392123B2 (ja) 糖尿病治療のためのｃｔｐ系インスリンアナローグ
CN101993496B (zh) 双重调节血糖血脂融合蛋白及其制法和用途
AU2017269496B2 (en) MIC-1 compounds and use thereof
CN106459222A (zh) Mic‑1融合蛋白及其用途
JP2005519041A (ja) 長期作用を備えたインスリン分子
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
KR20160114082A (ko) 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
JP2022008474A (ja) プロトキシン－ｉｉ変異体及びその使用方法
KR20170120703A (ko) 프로톡신-ii 변이체 및 사용 방법
KR20230008846A (ko) 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
KR20160007295A (ko) 인슐린 아날로그
KR20170106373A (ko) 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체
RS65822B1 (sr) Novi insulinski analozi i njihova upotreba
KR20220112817A (ko) 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법
KR20150110677A (ko) N 말단 절단된 인슐린 유사체
JP2010535842A (ja) 速効型インスリンアナログ
RU2816595C2 (ru) Аналоги инсулина, характеризующиеся сниженной аффинностью связывания с рецепторами инсулина
HK1238651A1 (en) Biphasic single-chain insulin analogues
ZA200404273B (en) Insulin molecule having protracted time action.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination